Nail cancer can be deadly, but how dangerous it is depends almost entirely on when it’s caught. When detected early and still confined to the nail area, the five-year survival rate is as high as 97%. When diagnosed late, after it has spread to distant organs, that number drops to 15 to 20%. The core problem with nail cancer is that it’s frequently mistaken for something harmless, which delays diagnosis and allows the disease to progress.
What Nail Cancer Actually Is
The medical term is subungual melanoma, a type of skin cancer that starts in the pigment-producing cells beneath the fingernail or toenail. It belongs to a broader category called acral lentiginous melanoma, which develops on the palms, soles, and nail beds. Unlike the more common forms of melanoma linked to sun exposure, nail melanoma has no clear connection to UV radiation. It can appear on any finger or toe, but the great toe and thumb are the most frequent locations.
Although overall incidence rates are fairly similar across racial groups, nail melanoma carries outsized significance for people with darker skin. In non-Caucasian patients, acral lentiginous melanoma accounts for up to 75% of all melanoma diagnoses. This isn’t because it’s more common in these populations in absolute terms. It’s because the other forms of melanoma (the ones tied to sun damage) are far less frequent, making nail and sole melanomas a much larger share of total cases.
Survival Rates by Stage
The numbers tell a clear story: early detection is the dividing line between a very survivable cancer and a very dangerous one. The American Cancer Society’s staging data for melanoma, which applies to subungual melanoma, breaks down like this:
- Stage IA: 97% five-year survival, 95% at ten years
- Stage IB: 92% five-year survival, 86% at ten years
- Stage IIA: 81% five-year survival, 67% at ten years
- Stage IIB: 70% five-year survival, 57% at ten years
- Stage IIC: 53% five-year survival, 40% at ten years
- Stage IIIA: 78% five-year survival, 68% at ten years
- Stage IIIB: 59% five-year survival, 43% at ten years
- Stage IIIC: 40% five-year survival, 24% at ten years
- Stage IV: 15 to 20% five-year survival, 10 to 15% at ten years
The steep drop between early and late stages reflects what happens when melanoma spreads beyond the original site. Once it reaches the lymph nodes (Stage III) or distant organs like the lungs, liver, or brain (Stage IV), treatment becomes much harder and outcomes worsen significantly.
Why Nail Cancer Is Often Caught Late
The biggest threat with nail cancer isn’t the biology of the tumor itself. It’s the delay in diagnosis. A dark streak under a nail can easily be mistaken for a bruise, a fungal infection, or trauma from stubbing a toe. This happens to patients and doctors alike. One published case in BMJ Case Reports documented a patient who went 18 months with a nail abnormality on his thumb before receiving a correct diagnosis. That kind of delay is not unusual.
Common misdiagnoses include fungal nail infections, chronic trauma, and subungual hematoma (a blood blister under the nail). The visual overlap between these conditions and early melanoma is genuinely tricky, especially on toenails that may already look discolored from shoe friction or minor injuries. Research on subungual melanoma patients found that the median tumor thickness at diagnosis was 2.1 mm, which is already deep enough to be concerning. Toenail melanomas tend to be even thicker at diagnosis than fingernail ones (3.5 mm versus 2.5 mm on average), likely because toenails get less visual attention.
Tumor thickness matters enormously. In one study, patients whose cancer had spread to nearby lymph nodes had a median tumor depth of 4 mm. Three out of five of those patients died of the disease within 40 months. By contrast, melanoma caught while it’s still “in situ,” meaning it hasn’t invaded deeper tissue, is nearly always curable.
Warning Signs to Recognize
Dermatologists use an ABCDEF mnemonic specifically for nail melanoma:
- A (Age and ancestry): Peak incidence falls between the 50s and 70s. African American, Asian, and Native American populations see a higher proportion of their melanoma cases in the nail unit.
- B (Band): A brown or black longitudinal band on the nail, especially one 3 mm or wider with irregular or blurred borders.
- C (Change): A nail band that changes in width, color, or shape over time, or a nail abnormality that doesn’t improve with treatment for other conditions.
- D (Digit): The thumb and great toe are the most commonly affected digits.
- E (Extension): Pigment that spreads beyond the nail onto the surrounding skin fold. This is called Hutchinson’s sign and is one of the strongest clinical indicators of melanoma.
- F (Family history): A personal or family history of melanoma or atypical moles raises risk.
Not every dark streak on a nail is cancer. Many people, particularly those with darker skin, have benign pigmented bands that are completely harmless. The key warning signs are a new streak that appears on a single nail, especially one that’s widening, darkening, or accompanied by pigment spreading onto the skin around the nail.
How Nail Cancer Is Diagnosed
A definitive diagnosis requires a biopsy of the nail matrix, the tissue at the base of the nail where new nail cells are produced. Several techniques exist, including punch biopsy (removing a small cylindrical sample), longitudinal excision (taking a narrow strip along the length of the nail), and transverse matrix excision (removing a horizontal section). The choice depends on the size and location of the suspicious area.
Nail biopsies are more involved than a standard skin biopsy because the nail plate usually needs to be partially or fully removed to access the tissue underneath. The procedure is done under local anesthesia, and the nail typically regrows, though sometimes with a permanent ridge or slight deformity depending on how much matrix tissue was sampled.
Treatment and What It Involves
For melanoma that hasn’t spread, treatment is surgical. Historically, this meant amputating the affected finger or toe at the nearest joint. That approach is still used for thicker, more advanced tumors, but for thinner melanomas caught early, more conservative surgery that preserves the digit is increasingly common. The goal is to remove the tumor with clear margins while sparing as much function as possible.
Early in situ disease can sometimes be managed with wide local excision, removing the tumor and a margin of surrounding healthy tissue without amputation. However, undertreatment of early disease has been linked to local recurrence. In one study, four out of six patients with in situ disease who were initially treated with wide excision eventually required amputation anyway.
For advanced cases where the cancer has reached lymph nodes or spread to other organs, treatment expands to include immunotherapy and other systemic treatments. These have improved outcomes for advanced melanoma in recent years, though Stage IV disease remains very difficult to treat. A sentinel lymph node biopsy, where surgeons check the closest lymph node for cancer cells, is commonly performed alongside surgery to determine whether the cancer has begun to spread. In one study of subungual melanoma patients, 17% had positive sentinel lymph nodes, and four out of five of those patients developed recurrence within about 16 months.
The Bottom Line on Lethality
Nail cancer is not inherently a death sentence, but it becomes far more dangerous the longer it goes undetected. The disease itself responds well to treatment when caught early, with survival rates above 90% for Stage I. The real danger is the delay: a dark streak dismissed as a bruise for a year, a toenail change chalked up to a fungal infection. By the time symptoms become impossible to ignore, the tumor may already be deep enough to have spread. If you notice a new, persistent dark band on a single nail, particularly one that’s growing or changing, getting it evaluated with a biopsy is the single most important step you can take.